City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...
InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration ...
Pre-tax losses at the main Irish unit of eye care product firm, Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.
Character Biosciences announced a collaboration with Bausch + Lomb with an initial focus on developing innovative treatments ...
Bausch + Lomb moved to bolster the eye-care company's pipeline of clinical-stage offerings with the acquisition of Whitecap Biosciences, a firm developing two therapies for potential use in glaucoma ...
City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal ...
Jersey City-based Character Biosciences has announced a collaboration with Bausch + Lomb to develop innovative treatments for ...
Bausch + Lomb Corporation (NYSE ... XIIDRA is a treatment for dry eye disease while MEIBO is the first and only prescription eye drop that directly targets tear evaporation to treat the signs ...
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has acquired Whitecap Biosciences, ...
Character Biosciences, a pioneer in genetics-guided drug discovery and development, today announced a collaboration with Bausch + Lomb, a leading global eye health company, to develop innovative ...
Pre-tax losses at the main Irish unit of eye care product firm Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the commercial launch of the enVista Aspire ...